<p>Unfavourable treatment outcomes in Multidrug-resistant Tuberculosis patients with Human immunodeficiency co-infected (MDR-TB/HIV) continues to be a global issue of concern. The suggested WHO treatment success rate is 90%, however the current percentage of treatment success is still low (59%), posing a significant threat to TB control. This study aimed to identify determinants of treatment outcomes among MDR-TB /HIV co-infected in Tanzania from 2017-2019.</p>